MPN EDUCATION FOUNDATION
The MPN Education Foundation is a 501(c)(3) non-profit organization run by volunteer MPN patients. It was incorporated in early 2004 at the urging of Dr. Ayalew Tefferi of Mayo Clinic (Rochester). The initial thrust of the Foundation was to continue the information/education/support goals of Dr. Harriet Gilbert through her MPN Research Center, which unfortunately died when she did in 2003. Our co-founder, Joyce Niblack(who passed in 2009), was a patient volunteer for Dr. Gilbert's center and Editor of the MPD VOICE newsletter.
The Foundation's first major project was to co-sponsor the Mayo Clinic Comprehensive Cancer Center/MPN Education Foundation patient conference held at Mayo Clinic Scottsdale February 25-27, 2005. This is the third such conference as co-founders Joyce and Bob Niblack worked with Mayo on the 2001 and 2003 conferences as well.
The Foundation's second major project was publication of the JAK2 issue of the MPD VOICE newsletter. That issue (Volume 1, Issue 1) was followed by an issue dealing with Myelofibrosis (Volume 2, Issue 1), announcement of the 2007 conference (Vol. 2, Issue 2), then Volume 3, Issue 1 focussed on results of a survey on fatigue and Quality of Life in the myeloproliferative
The patient conferences are scheduled every two years, and the most recent one was held in February 2013. The next conference, now called the Joyce Niblack Memorial Conference, will be held in 2015.
Dr. Tefferi's vision has expanded for our Foundation and the mission goals now include
Designed to advance research, knowledge about our diseases, develop new drugs for FDA approval, improve quality of life and care of MPN patients, etc.
The Scientific Advisory Board for the Foundation comprises:
The Board of directors comprises:
One of the Foundation's goals is encouraging MPN researchers/experts to take advantage of the MPN-Net online support group with approximately 3000 members from around the world as well as patients who come to www.mpninfo.org for information. The first group to take advantage of this opportunity was led by D. Gary Gilliland, MD, PhD at Harvard who accrued patients for their study that screened blood samples and DNA swabs from 345 on-line participants. The results yielded identification of the JAK2 mutation expressed by many MPN patients. This has been reported in the literature by Dr. Gilliland's group and confirmed by at least 6 independent other groups in the US and Europe.
This breakthrough discovery has lead to many new trial drug therapies for non-CML MPNs. CML was the first of the myeloproliferative neoplasms to benefit from the discovery of the bcr-abl tyrosine kinase inhibitor, Gleevec which changed the face of treatment for CML patients.
In a third study announced on MPN-NET, members of MPN-NET online support group participated in a Quality of Life Survey designed by MPN experts at Mayo, Harvard and MD Anderson designed to help the experts better understand the effects of fatigue on quality of life for those suffering from an MPN. The citation for the published results is: